Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
67 hedge funds and large institutions have $86.2M invested in Soleno Therapeutics in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 9 closing their positions.
38% more call options, than puts
Call options by funds: $146K | Put options by funds: $106K
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
10% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 20
2% more funds holding
Funds holding: 66 → 67 (+1)
0.05% more ownership
Funds ownership: 3.69% → 3.74% (+0.05%)
22% less capital invested
Capital invested by funds: $110M → $86.2M (-$24.2M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$4.87M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$856K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$723K |
| 4 |
State Street
Boston,
Massachusetts
|
+$647K |
| 5 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
+$474K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$7.63M |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$526K |
| 3 |
Goldman Sachs
New York
|
-$437K |
| 4 |
Two Sigma Advisers
New York
|
-$425K |
| 5 |
Squarepoint
New York
|
-$385K |
SLNO Hedge Fund Activity: Q4 2020 in Review
67 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q4 2020, worth a combined $86.2M — down 22% from $110M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new SLNO positions and 9 closed out — a net gain of 1 holder — while 22 added to existing stakes and 20 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $4.87M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $7.63M sold.
- 67 institutional investors held Soleno Therapeutics (SLNO) as of Q4 2020, up from 66 in Q3 2020.
- Funds reported $86.2M of Soleno Therapeutics stock for Q4 2020, down 22% quarter-over-quarter.
- 10 funds opened new Soleno Therapeutics positions in Q4 2020 and 9 closed out, a net change of +1 holder.
- The largest Soleno Therapeutics buyer in Q4 2020 was Suvretta Capital Management, an estimated $4.87M added.
- The largest Soleno Therapeutics seller in Q4 2020 was Consonance Capital Management, an estimated $7.63M sold.
Based on aggregated 13F filings for Q4 2020.